Literature DB >> 11276406

Antidepressant treatment in children and adolescents: bridging the gap between efficacy and effectiveness.

J M Zito1, D J Safer.   

Abstract

This review of antidepressant treatments in children and adolescents emphasizes the gap between efficacy data derived from randomized clinical trials (RCTs) and the limited effectiveness data from community-based practices. Part one is a brief review of data from randomized, double-blind clinical trials to assess the evidence base for the major approved indications for antidepressants in youths. Part two reviews information gaps in the evidence from RCTs. Part three discusses nonexperimental evidence of the use of antidepressants, including surveys of prescription sales, physician surveys, and population-based data. Part four presents a comprehensive model for assessing the use of antidepressants in youths in the community. The model aims to answer a range of public health-oriented questions and is intended to improve treating physicians' and clinical care providers' ability to manage medications for optimal patient benefit. Suggestions are made for engaging health service providers, health insurers, academicians, advocates, and the government in building the necessary infrastructure to make effectiveness as vital as efficacy to the model of drug therapy evaluation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11276406     DOI: 10.1007/s11920-001-0008-z

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  49 in total

Review 1.  The failure of placebo-controlled studies. ECNP Consensus Meeting, September 13, 1997, Vienna. European College of Neuropsychopharmacology.

Authors:  S A Montgomery
Journal:  Eur Neuropsychopharmacol       Date:  1999-03       Impact factor: 4.600

2.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

3.  Early termination of antidepressant drug treatment.

Authors:  M Linden; H Gothe; R W Dittmann; B Schaaf
Journal:  J Clin Psychopharmacol       Date:  2000-10       Impact factor: 3.153

4.  Trends in the prescribing of psychotropic medications to preschoolers.

Authors:  J M Zito; D J Safer; S dosReis; J F Gardner; M Boles; F Lynch
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

5.  Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up.

Authors:  J G Simeon; V F Dinicola; H B Ferguson; W Copping
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1990       Impact factor: 5.067

6.  Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder.

Authors:  B Geller; T B Cooper; D L Graham; H H Fetner; F A Marsteller; J M Wells
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1992-01       Impact factor: 8.829

7.  An open naturalistic trial of fluoxetine in adolescents and young adults with treatment-resistant major depression.

Authors:  C Boulos; S Kutcher; D Gardner; E Young
Journal:  J Child Adolesc Psychopharmacol       Date:  1992       Impact factor: 2.576

8.  Childhood enuresis. II. Psychopathology, tricyclic concentration in plasma, and antienuretic effect.

Authors:  J L Rapoport; E J Mikkelsen; A Zavadil; L Nee; C Gruenau; W Mendelson; J C Gillin
Journal:  Arch Gen Psychiatry       Date:  1980-10

9.  School phobia: a therapeutic trial with clomipramine and short-term outcome.

Authors:  T Berney; I Kolvin; S R Bhate; R F Garside; J Jeans; B Kay; L Scarth
Journal:  Br J Psychiatry       Date:  1981-02       Impact factor: 9.319

10.  Psychiatric disorder in adolescent offspring of parents with affective disorder in a non-referred sample.

Authors:  W R Beardslee; M B Keller; P W Lavori; G K Klerman; D J Dorer; H Samuelson
Journal:  J Affect Disord       Date:  1988 Nov-Dec       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.